191 related articles for article (PubMed ID: 11796368)
1. Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
Li X; Zhao X; Drlica K
Antimicrob Agents Chemother; 2002 Feb; 46(2):522-4. PubMed ID: 11796368
[TBL] [Abstract][Full Text] [Related]
2. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
3. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Browne FA; Clark C; Bozdogan B; Dewasse BE; Jacobs MR; Appelbaum PC
Int J Antimicrob Agents; 2002 Aug; 20(2):93-9. PubMed ID: 12297357
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
[TBL] [Abstract][Full Text] [Related]
5. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Black J; Moland ES; Chartrand SA; Thomson KS
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
[TBL] [Abstract][Full Text] [Related]
6. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Clark CL; Nagai K; Davies TA; Bozdogan B; Dewasse B; Jacobs MR; Appelbaum PC
Clin Microbiol Infect; 2002 Jun; 8(6):373-80. PubMed ID: 12084107
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
9. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
14. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
[TBL] [Abstract][Full Text] [Related]
15. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.
Houssaye S; Gutmann L; Varon E
Antimicrob Agents Chemother; 2002 Aug; 46(8):2712-5. PubMed ID: 12121964
[TBL] [Abstract][Full Text] [Related]
17. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.
Beyer R; Pestova E; Millichap JJ; Stosor V; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 2000 Mar; 44(3):798-801. PubMed ID: 10681364
[TBL] [Abstract][Full Text] [Related]
18. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
19. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
20. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Johnson AP; Warner M; Livermore DM
Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
